Lariam

Mefloquine, the active ingredient in Lariam, is a quinoline-methanol antimalarial presented as a tablet for oral use. It is used for prophylaxis and treatment of malaria caused by susceptible Plasmodium species in adults and children.

GNH USA supplies Lariam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mefloquine is an antimalarial drug that acts against Plasmodium parasites.

- Prophylaxis of malaria: prevents infection in travelers and residents of endemic areas. - Treatment of acute malaria: clears parasites in symptomatic infection caused by susceptible Plasmodium species.

Mefloquine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Vomiting: occasional episodes after dosing. - Abdominal pain: cramping or discomfort. - Dizziness: transient light‑headedness. - Insomnia: difficulty falling or staying asleep. - Headache: mild to moderate tension‑type pain.

Serious or Rare Side Effects: - Neuropsychiatric reactions: anxiety, depression, psychosis, or seizures. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Cardiac arrhythmias: QT prolongation or other rhythm disturbances. - Hepatic toxicity: elevated liver enzymes or hepatitis. - Visual disturbances: blurred vision or photopsia. - Peripheral neuropathy: tingling or numbness in extremities.

Mefloquine requires careful assessment before use to minimise risk.

- Pregnancy: contraindicated (Category D) due to potential fetal harm. - Psychiatric history: evaluate for depression, anxiety, or psychosis before prescribing. - Concomitant medications: review for drugs that may affect cardiac rhythm or CNS. - Renal/hepatic impairment: consider dose adjustment or alternative therapy. - Driving or operating machinery: avoid if experiencing dizziness or visual changes. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Mefloquine can interact with several medicines; some require avoidance while others need monitoring.

Major Interactions (Avoid): - QT‑prolonging agents: increase risk of cardiac arrhythmia. - CYP3A4 inducers (e.g., carbamazepine, rifampicin): reduce mefloquine plasma levels. - Anticonvulsants: may diminish antimalarial efficacy.

Moderate Interactions (Monitor Closely): - Antacids: may affect absorption; separate dosing by at least 2 hours. - Warfarin: monitor INR for potential anticoagulant effect changes. - Oral contraceptives: efficacy may be reduced; advise additional contraceptive measures.